comprehensive -WSS

comprehensive

author：knowledge 2025-09-29 18:17:40 - browse：83377

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： HHS leader on health, climate change and biopharma emissions

leisure time

WSS

The explosion of genetic testing requires a new approach

FDA poised to publish guidelines for clinical trial diversity

NIH confirmation hearing shows politicization of research

FDA struggles to regulate food additives, sometimes for decades

Studies point to risks of excluding people with obesity from drug trials

Liver decline slowed by off

explore

comprehensive

hotspot

Heart attack and stroke risk calculators need revising

Why health workers in Gaza are injured or die at high rates

Virginia high school admissions case could be legal follow

ASCO eve: Let’s set the table for this year's meeting

State Dept. review finds Biden bears some blame for Afghanistan failures

Hospital price transparency does save money, advocate argues

Moonlake's readout produced a cash windfall. Risks remain

The explosion of genetic testing requires a new approach

Dobbs anniversary: the lost opportunity of abortion as health care

Citing H5N1 threat, CDC urges peak flu monitoring this summer

hotspot

Will Ozempic

Eyeing GLP

Investigation reveals sickle cell patients pressured into sterilizations

NIH confirmation hearing shows politicization of research

STAT Summit: How a Chicago ER doctor tackles gun violence

Why health workers in Gaza are injured or die at high rates

focus

entertainment

leisure time

focus